Please	type :	a plus	sign ((+)	inside	this box
1 ICOSC	Type I	u pius	21KH	,	11121/1/0	UIID OUA

PTO/SB/08B (10-96)

Approved for use through 10-31-99. OMB (0651-003

	Patent and Trademark Office: U.S.	DEPARTMENT	OF COMMERCE
ersons are required to respond to	a collection of information unless	it contains a smlid (OMB control num

Under the Paperwork Reduction Act of 1995, no person	s are required to respond to a collection of info	rmation unless it contains a valid OMB control number.	
Substitute for form 1449B/PTO	COMPLETE IF KNOWN		
INFORMATION DISCLOSURE	Application Number	09/700,669	
STATEMENT BY APPLICANT	Filing Date	January 3, 2001	
AUS 0 1 2003 (use as many sheets as necessary)	First Named Inventor	VAN ASBECK, et al.	
(use as manusheets as necessary)	Group Art Unit	1636	
d TRADEILE TO	Examiner Name	J.S. KETTER	
Sheet 1 of 1	Attorney Docket Number	30394-1041	

Examiner Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T²
M	-	REMICK, S.C., et al., "Continuous Infusio ClinicalOncology, Vol. 12, No. 6, pp 1130	AIDS-Related Kaposi's Sarcoma," J of 94)		
	_				
·					
		_			
					
Examiner Signature	V.	10	Date Considered	5/12/04	1

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[G:\ANNETTE\L&S-VanAsbeck-1449.PTO.doc]

Unique citation designation number. 2. Applicant is to place a check mark here if English language Translation is attached.